A 5-gene classifier from the carcinoma-associated fibroblast transcriptomic profile and clinical outcome in colorectal cancer

Oncotarget

Volumn 5, Issue 15, 2014, Pages 6437-6452

  Berdiel Acer, Mireia ^a   Berenguer, Antoni ^a   Sanz Pamplona, Rebeca ^a   Cuadras, Daniel ^a   Sanjuan, Xavier ^b   Paules, Maria José ^b   Santos, Cristina ^a   Salazar, Ramon ^a   Moreno, Victor ^a   Capella, Gabriel ^a   Villanueva, Alberto ^a   Molleví, David G ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Carcinoma associated fibroblast; Colorectal; Genetic classifier; Microenvironment; Prognosis

Indexed keywords

ADULT; AGED; AMIGO2 GENE; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CARCINOMA ASSOCIATED FIBROBLAST; CCL11 GENE; CLASSIFIER; COLORECTAL CANCER; FEMALE; FIBROBLAST; GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PDLIM3 GENE; PREDICTIVE VALUE; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLC7A2 GENE; TRANSCRIPTOMICS; ULBP2 GENE; CLASSIFICATION; COHORT ANALYSIS; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION;

TRANSCRIPTOME;

AGED; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FIBROBLASTS; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84906266778     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2237     Document Type: Article

References (48)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127(12): 2893-2917.
2. O'Connell JB, Maggard MA and Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004; 96(19):1420-1425.
3. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I and de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. The New England journal of medicine. 2004; 350(23):2343-2351.
4. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS and Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007; 370(9604):2020-2029.
5. Ragnhammar P, Hafstrom L, Nygren P and Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta oncologica (Stockholm, Sweden). 2001; 40(2-3):282-308.
6. Van Schaeybroeck S, Allen WL, Turkington RC and Johnston PG. Implementing prognostic and predictive biomarkers in CRC clinical trials. Nature reviews. 2011; 8(4): 222-232.
7. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T and et al. A gene-expression signature as a predictor of survival in breast cancer. The New England journal of medicine. 2002; 347(25):1999-2009.
8. Sun Z, Wigle DA and Yang P. Non-overlapping and noncell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol. 2008; 26(6):877-883.
9. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB and et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nature medicine. 2002; 8(8):816-824.
10. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM and Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. The Journal of clinical investigation. 2004; 113(6):913-923.
11. Sanz-Pamplona R, Berenguer A, Cordero D, Riccadonna S, Sole X, Crous-Bou M, Guino E, Sanjuan X, Biondo S, Soriano A, Jurman G, Capella G, Furlanello C and Moreno V. Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review. PloS one. 2012; 7(11):e48877.
12. Webber EM, Lin JS and Evelyn PW. Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction. PLoS Curr. 2. 2010
13. Tan IB and Tan P. Genetics: an 18-gene signature (ColoPrint(R)) for colon cancer prognosis. Nat Rev Clin Oncol. 2011, 8(3):131-133.
14. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, Bruin S, Kerr D, Kuppen P, van de Velde C, Morreau H, Van Velthuysen L and et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2011; 29(1):17-24.
15. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407):330-337.
16. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW and Hanahan D. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nature medicine. 2013; 19(5):619-625.
17. De Sousa EMF, Vermeulen L, Fessler E and Medema JP. Cancer heterogeneity-a multifaceted view. EMBO reports. 2013; 14(8):686-695.
18. Wang X, Markowetz F, De Sousa EMF, Medema JP and Vermeulen L. Dissecting cancer heterogeneity -An unsupervised classification approach. The international journal of biochemistry & cell biology. 2013; 45(11):2574-2579.
19. Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV, Sevillano M, Nadal C, Jung P, Zhang XH, Byrom D, Riera A, Rossell D, Mangues R, Massague J, Sancho E and et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012; 22(5): 571-584.
20. De Wever O and Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol. 2003; 200(4):429-447.
21. Meads MB, Gatenby RA and Dalton WS. Environmentmediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009; 9(9):665-674.
22. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL and et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-752.
23. Noguera R, Nieto OA, Tadeo I, Farinas F and Alvaro T. Extracellular matrix, biotensegrity and tumor microenvironment. An update and overview. Histology and histopathology. 2012; 27(6):693-705.
24. Ingber DE. Cancer as a disease of epithelial-mesenchymal interactions and extracellular matrix regulation. Differentiation; research in biological diversity. 2002; 70(9-10)547-560.
25. Herrera M, Islam AB, Herrera A, Martin P, Garcia V, Silva J, Garcia JM, Salas C, Casal I, de Herreros AG, Bonilla F and Pena C. Functional heterogeneity of cancerassociated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin Cancer Res. 2013; 19(21):5914-5926.
26. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M and Park M. Stromal gene expression predicts clinical outcome in breast cancer. Nature medicine. 2008; 14(5):518-527.
27. de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ, Kuppen PJ, Tollenaar RA and Mesker WE. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast cancer research and treatment. 2011; 125(3):687-696.
28. Dekker TJ, van de Velde CJ, van Pelt GW, Kroep JR, Julien JP, Smit VT, Tollenaar RA and Mesker WE. Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Breast cancer research and treatment. 2013; 139(2):371-379.
29. Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, Domingo E, Smit VT, Midgley R, Warren BF, Johnstone EC, Kerr DJ and Mesker WE. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol. 2013; 24(1):179-185.
30. Tsujino T, Seshimo I, Yamamoto H, Ngan CY, Ezumi K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N and Monden M. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res. 2007; 13(7): 2082-2090.
31. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D and Brown PO. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS biology. 2004; 2(2):E7.
32. Navab R, Strumpf D, Bandarchi B, Zhu CQ, Pintilie M, Ramnarine VR, Ibrahimov E, Radulovich N, Leung L, Barczyk M, Panchal D, To C, Yun JJ, Der S, Shepherd FA, Jurisica I and et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(17):7160-7165.
33. Gao Q, Wang XY, Qiu SJ, Zhou J, Shi YH, Zhang BH and Fan J. Tumor stroma reaction-related gene signature predicts clinical outcome in human hepatocellular carcinoma. Cancer science. 2011; 102(8):1522-1531.
34. Perez-Villamil B, Romera-Lopez A, Hernandez-Prieto S, Lopez-Campos G, Calles A, Lopez-Asenjo JA, Sanz-Ortega J, Fernandez-Perez C, Sastre J, Alfonso R, Caldes T, Martin-Sanchez F and Diaz-Rubio E. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC cancer. 2012; 12:260.
35. Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Flejou JF, Benchimol D, Berger A and Lagarde A. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS medicine. 2013; 10(5):e1001453.
36. Budinska E, Popovici V, Tejpar S, D'Ario G, Lapique N, Sikora KO, Di Narzo AF, Yan P, Hodgson JG, Weinrich S, Bosman F, Roth A and Delorenzi M. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol. 2013; 231(1):63-76.
37. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, Snel MH, Chresta CM, Rosenberg R, Nitsche U, Macarulla T, Capella G, Salazar R, Orphanides G, Wessels LF, Bernards R and et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer. 2014; 134(3):552-562.
38. De Sousa EMF, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, de Jong JH, de Boer OJ, van Leersum R, Bijlsma MF, Rodermond H, van der Heijden M, van Noesel CJ, Tuynman JB, Dekker E, Markowetz F and et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nature medicine. 2013; 19(5):614-618.
39. Bauer M, Su G, Casper C, He R, Rehrauer W and Friedl A. Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast. Oncogene. 2010; 29(12):1732-1740.
40. Lim KP, Cirillo N, Hassona Y, Wei W, Thurlow JK, Cheong SC, Pitiyage G, Parkinson EK and Prime SS. Fibroblast gene expression profile reflects the stage of tumour progression in oral squamous cell carcinoma. J Pathol. 2011; 223(4):459-469.
41. Zhang C, Fu L, Fu J, Hu L, Yang H, Rong TH, Li Y, Liu H, Fu SB, Zeng YX and Guan XY. Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clin Cancer Res. 2009; 15(12):4017-4027.
42. Worthley DL, Giraud AS and Wang TC. Stromal fibroblasts in digestive cancer. Cancer Microenviron. 2010; 3(1): 117-125.
43. O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, Cowens JW and Wolmark N. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010; 28(25):3937-3944.
44. Jia Z, Rahmatpanah FB, Chen X, Lernhardt W, Wang Y, Xia XQ, Sawyers A, Sutton M, McClelland M and Mercola D. Expression changes in the stroma of prostate cancer predict subsequent relapse. PloS one. 2012; 7(8):e41371.
45. Andersen CL, Jensen JL and Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer research. 2004; 64(15): 5245-5250.
46. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A and Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome biology. 2002; 3(7):RESEARCH0034.
47. Pfaffl MW, Tichopad A, Prgomet C and Neuvians TP. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper-Excel-based tool using pair-wise correlations. Biotechnology letters. 2004; 26(6):509-515.
48. Silver N, Best S, Jiang J and Thein SL. Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR. BMC molecular biology. 2006; 7:33.